Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor + Bevacizumab + Atezolizumab in Advanced HCC
NCT05093608Phase 1Terminated
- Sponsor
- Moffitt Cancer Center
- Start
- Nov 2021
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of selinexor in hepatocellular carcinoma (HCC) (2 arms), sponsored by Moffitt Cancer Center. Primary endpoint: Maximum Tolerated Dose at 24 months. Started Nov 2021; status: terminated.
02
Drugs
selinexor
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05093608.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05093608.